Kalkine has a fully transformed New Avatar.

Switch to Old version
1800-272-662
Shopping Cart 0
countryflagAU
Login

Cyclopharm Ltd

Healthcare AU CYC

0.74AUD
0.01(1.37%)

Last update at 2026-03-10T23:57:00Z

Day Range

0.740.74
LowHigh

52 Week Range

0.561.55
LowHigh

Fundamentals

  • Previous Close 0.73
  • Market Cap89.85M
  • Volume3542
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-16.66264M
  • Revenue TTM32.33M
  • Revenue Per Share TTM0.29
  • Gross Profit TTM 17.85M
  • Diluted EPS TTM-0.16

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -17.85668M -13.07145M -4.18973M -6.02985M -4.34687M
Minority interest - - - - -
Net income -17.21991M -13.19762M -4.70081M -6.61151M -5.04017M
Selling general administrative - 21.48M 14.00M 10.96M 10.30M
Selling and marketing expenses - 3.15M 2.05M 2.92M 1.02M
Gross profit -1.45925M 17.93M 16.08M 15.78M 12.66M
Reconciled depreciation - 1.48M 0.94M 0.93M 0.76M
Ebit -18.18237M -14.52457M -4.77391M -5.96241M -4.33036M
Ebitda -16.41237M -13.68988M -3.83508M -5.03093M -3.57163M
Depreciation and amortization 1.77M 0.83M 0.94M 0.93M 0.76M
Non operating income net other - - - - -
Operating income -18.18237M -14.34688M -5.26308M -5.96241M -4.33036M
Other operating expenses 50.51M 41.92M 36.36M 30.85M 24.66M
Interest expense 0.63M 0.32M 0.22M 0.07M 0.02M
Tax provision - 0.13M 0.51M 0.58M 0.69M
Interest income - 0.67M 0.49M 0.11M 0.09M
Net interest income - 0.35M 0.27M -0.15619M -0.08536M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense -0.63678M 0.13M 0.51M 0.58M 0.69M
Total revenue 32.33M 27.57M 26.34M 23.22M 17.70M
Total operating expenses 16.72M 32.28M 13.72M 23.41M 19.61M
Cost of revenue 33.78M 9.64M 22.64M 7.44M 5.04M
Total other income expense net 0.33M 1.45M 5.84M -0.06743M -0.01651M
Discontinued operations - - - - -
Net income from continuing ops - -13.19762M -4.70081M -6.61151M -5.04017M
Net income applicable to common shares - -13.19762M -4.70081M -6.61152M -5.04017M
Preferred stock and other adjustments - - - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 46.10M 62.13M 45.91M 49.54M 55.74M
Intangible assets 1.70M 4.18M - 4.57M 4.56M
Earning assets - - - - -
Other current assets 1.81M 2.43M 0.45M 0.57M 0.39M
Total liab 18.99M 19.40M 13.65M 13.01M 12.67M
Total stockholder equity 27.11M 42.73M 32.26M 36.54M 43.07M
Deferred long term liab - - - 0.79M 0.79M
Other current liab 6.64M 6.19M 5.27M 3.33M 5.07M
Common stock 87.07M 92.41M 63.78M 63.42M 62.97M
Capital stock - - - 63.42M 62.97M
Retained earnings -65.07600M -47.85609M -34.65847M -29.07283M -21.57873M
Other liab - - - 0.95M 0.92M
Good will 0.97M 0.93M 0.90M 0.87M 0.87M
Other assets - - 0.00000M 0.64M 1.61M
Cash 6.63M 20.57M 11.73M 20.30M 29.25M
Cash and equivalents - - - - -
Total current liabilities 11.26M 10.61M 8.67M 7.94M 7.42M
Current deferred revenue - - 0.04M - -
Net debt 8.29M -12.28213M -7.49913M -15.96459M -24.73949M
Short term debt 0.56M 0.63M 0.21M 0.21M 0.18M
Short long term debt - - - - -
Short long term debt total 14.92M 8.29M 4.23M 4.33M 4.51M
Other stockholder equity - -0.00000M - -1.05313M -3.66114M
Property plant equipment - - - 6.60M 6.25M
Total current assets 28.46M 42.39M 30.20M 36.87M 43.25M
Long term investments - - - - -
Net tangible assets - - - 31.89M 38.43M
Short term investments - 1.23M - - -
Net receivables 8.59M 4.91M 7.90M 7.71M 8.04M
Long term debt - - - - -
Inventory 11.43M 13.25M 10.12M 8.29M 5.51M
Accounts payable 4.06M 3.80M 3.15M 4.40M 2.17M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income 5.11M -1.82095M 3.14M 2.19M 1.67M
Additional paid in capital - - - - -
Common stock total equity - - - - -
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other - 1.53M 0.03M - -
Deferred long term asset charges - - - - -
Non current assets total 17.64M 19.74M 15.72M 12.67M 12.49M
Capital lease obligations - - - 4.33M 4.51M
Long term debt total - - - 4.12M 4.33M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments - -0.97186M -0.50847M -1.54840M -1.16102M
Change to liabilities - - - 1.08M 1.82M
Total cashflows from investing activities 3.00M -0.97186M -0.50847M -1.54840M -1.16102M
Net borrowings - - - -0.28942M -0.28871M
Total cash from financing activities -1.11851M 22.22M -1.01877M -0.72564M 30.17M
Change to operating activities - - - 0.74M 0.02M
Net income -17.21991M -13.19762M -4.70081M -6.61151M -5.04017M
Change in cash -13.94140M 8.84M -8.56975M -8.95308M 27.37M
Begin period cash flow 20.57M 11.73M 20.30M 29.25M 1.87M
End period cash flow 6.63M 20.57M 11.73M 20.30M 29.25M
Total cash from operating activities -17.32945M -12.57441M -7.19763M -5.68003M -1.62941M
Issuance of capital stock - 24.00M - - 33.00M
Depreciation 1.77M 1.48M 0.94M 0.93M 0.76M
Other cashflows from investing activities - -0.16832M -0.30117M - 0.00000M
Dividends paid - 0.00000M -0.88483M -0.88259M -0.88132M
Change to inventory -0.80894M -3.09184M -1.86318M -2.78129M -0.77536M
Change to account receivables -1.69352M 0.24M -0.49256M -0.58799M 0.69M
Sale purchase of stock - -1.14491M - 0.00000M -1.65778M
Other cashflows from financing activities -1.11851M 0.00593M 0.14M 0.16M -0.28871M
Change to netincome - - - 0.52M 0.75M
Capital expenditures 1.99M 0.97M 0.54M 1.55M 1.16M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital -2.85190M -2.60699M -1.93379M 0.45M 0.40M
Stock based compensation - 0.36M 0.52M - -
Other non cash items 0.97M 1.75M -0.97767M 5.68M 4.28M
Free cash flow -19.32147M -13.54626M -7.73563M -7.22843M -2.79043M

Peer Comparison

Sector: Healthcare Industry: Medical Distribution

Company Change (AUD) Price (AUD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
CYC
Cyclopharm Ltd		 0.01 1.37% 0.74 - 116.28 2.78 3.29 5.41 -24.5712
SIG
Sigma Healthcare Ltd		 -0.045 1.64% 2.71 56.00 38.17 3.39 6.43 5.56 40.06
EBO
Ebos Group Ltd		 -0.16 0.84% 18.88 18.43 17.01 0.31 1.51 0.47 10.81
PGC
Paragon Care Ltd		 -0.005 2.70% 0.18 - 5.98 0.09 0.98 0.18 17.79
MYX
Mayne Pharma Group Ltd		 0.13 5.26% 2.60 - 263.16 0.49 0.55 0.42 5.70

Reports Covered

Stock Research & News

View All

Profile

Cyclopharm Limited manufacture and sells medical equipment and radiopharmaceuticals in the Asia Pacific, Europe, Canada, the United States, and internationally. The company operates Technegas which offers diagnostic equipment and consumables used by physicians in the detection of pulmonary embolism and other respiratory conditions. It is also involved in the research and development; and distribution of third-party products to the diagnostic imaging sector. The company serves nuclear medicine departments. Cyclopharm Limited was founded in 1986 and is headquartered in Kingsgrove, Australia.

Cyclopharm Ltd

1 The Crescent, Kingsgrove, NSW, Australia, 2208

Key Executives

Name Title Year Born
Mr. James S. McBrayer F.A.C.I.D., BSPharm, GDM, FAICD, AIM CEO, MD, Company Sec. & Director 1965
Mr. Mathew Farag Chief Operating Officer NA
Mr. Graham N. Phillips Fin. Mang. NA
Dr. Mark Doverty Global Head of Regulatory Compliance & Clinical Research NA
Ms. Sally-Ann Cornelius Head of Sales NA
Ms. Niamh McAree Head of Quality and Regulatory NA
Mr. Chris Quinn Head of Service NA
Ms. Sui Ling Cheah Financial Controller 1970
Mr. Lynn McLauchlin Gen. Mang. of Canada NA
Mr. Gary T. Somerville Quality & Regulatory Mang. NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.